Gregory C. Hadlock, Ph.D. - Publications

Affiliations: 
2010 Pharmacology and Toxicology University of Utah, Salt Lake City, UT 
Area:
Pharmacology, Toxicology, Neuroscience Biology

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 1-9. PMID 23811290 DOI: 10.1016/j.nano.2013.06.010  0.6
2013 Charntikov S, Swalve N, Pittenger S, Fink K, Schepers S, Hadlock GC, Fleckenstein AE, Hu G, Li M, Bevins RA. Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine. Neuropharmacology. 75: 138-44. PMID 23916479 DOI: 10.1016/j.neuropharm.2013.07.019  0.6
2012 McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. The Journal of Pharmacology and Experimental Therapeutics. 340: 295-303. PMID 22034657 DOI: 10.1124/jpet.111.188433  0.6
2011 Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. The Journal of Pharmacology and Experimental Therapeutics. 339: 530-6. PMID 21810934 DOI: 10.1124/jpet.111.184119  0.6
2011 Hadlock GC, Nelson CC, Baucum AJ, Hanson GR, Fleckenstein AE. Ex vivo identification of protein-protein interactions involving the dopamine transporter. Journal of Neuroscience Methods. 196: 303-7. PMID 21291912 DOI: 10.1016/j.jneumeth.2011.01.023  0.6
2010 Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. Journal of Neurochemistry. 115: 325-32. PMID 20649837 DOI: 10.1111/j.1471-4159.2010.06922.x  0.6
2010 Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 335: 207-12. PMID 20622144 DOI: 10.1124/jpet.110.166660  0.6
2009 Hadlock GC, Baucum AJ, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. The Journal of Pharmacology and Experimental Therapeutics. 329: 169-74. PMID 19141713 DOI: 10.1124/jpet.108.145631  0.6
Show low-probability matches.